Impact of Formulation Variables on Meloxicam spanlastics Preparation

Authors

  • Lubna Sabri college of pharmacy , University of Baghdad
  • Mohammed Khalil Ministry of Health and Environment, Babylon Health Directorate, , Babylon, Iraq

DOI:

https://doi.org/10.31351/vol33iss4pp59%20-%2068

Keywords:

edge activators, injection method, Meloxicam, spanlastic, span 60

Abstract

Spanlastic is a modern drug delivery that combines vesicular and nanoparticulate characteristics with numerous advantages over topical applied conventional vesicular systems in terms of stablility, penetration flexibility, and targeting. Meloxicam (MX) is a potent non-steroid anti-inflammatory drug that is frequently utilized for the short- and long-term treatment of chronic pain and inflammatory diseases including rheumatoid arthritis. However, the oral administration of MX often includes several adverse effects, including gastrointestinal disturbances and ulceration. Thus, the aim is a preparation of proper formula for MX-loaded spanlastics via studying the formulation variables that may affect their properties using the ethanol injection method. Variables include;  span®60: edge activator ratio, the type of edge activators, the amount of MX, and the type of organic phase solvent were studied for their impact on particle size, polydispersity index, and entrapment efficiency. The formula that was selected showed sustained release for six hours, entrapment efficiency of 70.66±1.15%, zeta potential (-4.51), and particles that were 495±9.9 nm in size. Overall, the results indicated that spanlastics had the potential carrier for medicine delivery systems.

How to Cite

1.
Sabri L, Khalil M. Impact of Formulation Variables on Meloxicam spanlastics Preparation. Iraqi Journal of Pharmaceutical Sciences [Internet]. 2024 Dec. 20 [cited 2024 Dec. 21];33(4):59-68. Available from: https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/2826

Publication Dates

Received

2023-07-27

Revised

2023-07-31

Accepted

2023-10-16

Published Online First

2024-12-20

References

Ansari M D, Saifi Z, Pandit J, Khan I, Solanki P, Sultana Y , et al. Spanlastics a Novel Nanovesicular Carrier: Its Potential Application and Emerging Trends in Therapeutic Delivery. AAPS PharmSciTech. 2022; 23: 112.

2-Saleh A, Khalifa M, Shawky S, Bani-Ali A, Eassa H. Zolmitriptan Intranasal Spanlastics for Enhanced Migraine Treatment; Formulation Parameters Optimized via Quality by Design Approach. SciPharm. 2021; 89: 24.

Mazyed E A, Helal D A, Elkhoudary M M, Abd Elhameed A G, Yasser M. Formulation and Optimization of Nanospanlastics for Improving the Bioavailability of Green Tea Epigallocatechin Gallate. Pharmaceuticals. 2021; 14: 68.

Vindhya V S, Krishnananda Kamath K, Sandeep Kumar Jain, Shabaraya A R. Spanlastics: A Modern Formulation Approach in Drug Delivery. European Journal of Pharmaceutical and Medical Research. 2023; 10(4): 96-102.

Aziz D, Mohamed S A,Tayel S, Makhlouf A. Enhanced Ocular Anti-Aspergillus Activity of Tolnaftate Employing Novel Cosolvent-Modified Spanlastics: Formulation, Statistical Optimization, Kill Kinetics, Ex Vivo Trans-Corneal Permeation, In Vivo Histopathological and Susceptibility Study. Pharmaceutics 2022; 14: 1746.

Abdelmonem R, El-Enin HAA, Abdelkader G, Abdel-Hakeem M. Formulation and characterization of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment. Drug Deliv. 2023;30(1):2163321.

Almuqbil RM, Sreeharsha N,Nair AB. Formulation-by-Design of Efinaconazole Spanlastic Nanovesicles for Transungual Delivery Using Statistical Risk Management and Multivariate Analytical Techniques. Pharmaceutics. 2022; 14: 1419.

Mekkawy AI, Eleraky NE, Soliman GM, Elnaggar MG, Elnaggar MG. Combinatorial Therapy of Letrozole- and Quercetin-Loaded Spanlastics for Enhanced Cytotoxicity against MCF-7 Breast Cancer Cells. Pharmaceutics. 2022; 14: 1727.

Al-hassani HR, Al-khedairy EBH. Formulation and In-Vitro Evaluation of Meloxicam Solid Dispersion using Natural Polymers . Iraqi J Pharm Sci. 2021;30(1):169–78.

Muhammed SA, Al-Kinani KK. Formulation and in vitro evaluation of meloxicam as a self-microemulsifying drug delivery system. F1000Res. 2023;12:315.

Nief R A, Hussein AA. Preparation and Evaluation of Meloxicam Microsponges as Transdermal Delivery System. Iraqi J Pharm Sci. 2014;.23: 62-74.

Drais HK, Hussein AA. Drais, Hayder Kadhim, and Ahmad A. Hussein. Formulation characterization and evaluation of meloxicam nanoemulgel to be used topically. Iraqi J Pharm Sci. 2017; 26 (1): 9-16.

Alwan LA, Al-Akkam EJ. Formulation and evaluation of transdermal dissolved microneedles patches for meloxicam. Int J Drug Deliv Technol. 2021;11(3):656–62.

Abdelbari MA, El-Mancy SS, Elshafeey AH, Abdelbary AA. Implementing spanlastics for improving the ocular delivery of clotrimazole: In vitro characterization, ex vivo permeability, microbiological assessment and in vivo safety study. Int J Nanomedicine. 2021;16:6249–61.

Hamed SB, Abd Alhammid S N. Formulation and Characterization of Felodipine as an Oral Nanoemulsions. Iraqi J Pharm Sci. 2021; 30(1): 209-217.

Younus Alkwak R S and Rajab N A. Lornoxicam-Loaded Cubosomes: Preparation and In vitro Characterization. Iraqi J Pharm Sci. 2022; 31(1): 144-153.

Noor A H, Ghareeb MM. Formulation and Evaluation of Ondansetron HCl Nanoparticles for Transdermal Delivery. Iraqi J Pharm Sci. 2020; 29(2): 70-78.

Sabri LA, Khasraghi AH, Sulaiman HT. Preparation and evaluation of oral soft chewable jelly containing flurbiprofen. J Adv Pharm Technol Res. 2022;13(4):306-311.

Sabri LA, Hussein AA. Comparison between Conventional and Supersaturable Self-nanoemulsion Loaded with Nebivolol: Preparation and In-vitro/Ex-vivo Evaluation. Iraqi J Pharm Sci. 2020; 29(1): 2016-225.

Zidan AS, Mokhtar Ibrahim M, Megrab NAE. Optimization of methotrexate loaded niosomes by Box–Behnken design: An understanding of solvent effect and formulation variability. Drug Dev Ind Pharm. 2017; 43: 1450–1459.

Obeid MA, Haifawi S, Khadra I. The impact of solvent selection on the characteristics of niosome nanoparticles prepared by microfluidic mixing. Int J Pharm. 2023; 5:100168.

Farghaly DA, Aboelwafa AA, Hamza MY, Mohamed MI. Topical Delivery of Fenoprofen Calcium via Elastic Nano-vesicular Spanlastics: Optimization Using Experimental Design and In Vivo Evaluation. AAPS PharmSciTech. 2017;18(8):2898-2909.

Badria FA, Fayed HA, Ibraheem AK, State AF, Mazyed EA. Formulation of Sodium Valproate Nanospanlastics as a Promising Approach for Drug Repurposing in the Treatment of Androgenic Alopecia. Pharmaceutics. 2020 Sep 11;12(9):866.

Ghozzy OM, Abdelghani GM, Elsabbagh HM. Formulation, Characterization and Ex Vivo skin Permeation of Caffeine Loaded Spanlastic Nanovesicles. IOSR Journal of Pharmacy.2020; 10(2): 1-15.

Nemr AA, El-Mahrouk GM, Badie HA. Development and evaluation of surfactant-based elastic vesicular system for transdermal delivery of Cilostazole: ex-vivo permeation and histopathological evaluation studies. J Liposome Res. 2022;32(2):159-171.

Elsherif NI, Shamma RN, Abdelbary G. Terbinafine Hydrochloride Trans-ungual Delivery via Nanovesicular Systems: In Vitro Characterization and Ex Vivo Evaluation. AAPS PharmSciTech. 2017;18(2):551-562.

Khan M I, Yaqoob S, Madni A, Akhtar MF , Sohail MF, Saleem A, et al. Development and In Vitro/Ex Vivo Evaluation of Lecithin-Based Deformable Transfersomes and Transfersome-Based Gels for Combined Dermal Delivery of Meloxicam and Dexamethasone. Biomed Res Int. 2022; 2022:ID 8170318, 1-16.

Nasr A, Gardouh A, Ghorab M. Novel Solid Self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of olmesartan medoxomil: Design, formulation, pharmacokinetic and bioavailability evaluation. Pharmaceutics. 2016; 8(20):1-29.

Ab Aziz NA, Salim N, Saari N, Md Yusoff F,Zarei M. Jellyfish collagen hydrolysateloaded niosome for topical application: Formulation development, antioxidant andantibacterial activities. J Sustain Sci Manag. 2022; 17: 1–17.

Samra MM, Sadia A, Azam M, Imran M, Ahmad I, Basra MAR. Synthesis, Spectroscopic and Biological Investigation of a New Ca(II) Complex of Meloxicam as Potential COX-2 Inhibitor. Arabian Journal for Science and Engineering. 2022; 47:7105–22.

Abdellatif AAH, Aldosari BN, Al-Subaiyel A, Alhaddad A, Samman WA, Eleraky NE, et al. Transethosomal Gel for the Topical Delivery of Celecoxib: Formulation and Estimation of Skin Cancer Progression. Pharmaceutics. 2023; 15: 22.

Downloads

Published

2024-12-20